Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G withdraws Intrinsa NDA

Executive Summary

Procter & Gamble withdraws NDA for female testosterone patch Intrinsa, but plans to resubmit the application for the hypoactive sexual desire disorder treatment with additional data from trials in naturally menopausal women. The trials are "nearly complete," the company said. At its Dec. 2 meeting, the Reproductive Health Drugs Advisory Committee agreed that additional safety data is needed because of the potential for broad off-label use (1"The Pink Sheet" Dec. 6, 2004, p. 18). The company was seeking an indication for use in surgically menopausal women...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS045196

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel